This article is more than 5 years old. Information may no longer be current.

Hydrus reduces IOP in comparison trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

David F. Chang

WASHINGTON — Data from the COMPARE trial for the Hydrus microstent vs. two iStents as a stand-alone treatment for open-angle glaucoma showed some advantages for the Hydrus, according to a speaker here.

“In the comparison, Hydrus was statistically superior in lowering the medication count, the number of eyes that were completely medication free at a year, the number of eyes in terms of preventing them from requiring three or more medications, and then in addition reducing the IOP by an additional 20%,” David F. Chang, MD, said at the American Society of Cataract and Refractive Surgery annual meeting.

The prospective, multicenter, randomized COMPARE trial included patients with mild to moderate open-angle glaucoma who were taking two or more medications. Patients were randomly assigned 1:1 to either the Hydrus (Ivantis) group or the two iStent (Glaukos) group. Seventy-five patients were in the Hydrus group and 77 in the two iStent group.

At 12 months, 46.6% of Hydrus patients were required to take no medication compared with 24% of iStent patients, a statistically significant difference, Chang said.

“How many people remained on three or more medications? There were a number of these, and here again it was three times more likely with the two iStents that the patient would still be on that many medications,” he said.

Additionally, 72.6% of patients in the Hydrus group had a sustained reduction of at least one medication and at least a 20% drop in IOP compared with 46.7% of iStent patients, a statistically significant difference, he said.

The iStent is FDA approved for use with cataract surgery to reduce IOP in adults with mild to moderate open-angle glaucoma; Ivantis has submitted a premarket approval application to the FDA for the Hydrus to lower IOP in open-angle glaucoma. – by Robert Linnehan

References:

Chang DF. COMPARE Trial. Prospective, multicenter, randomized comparison of Hydrus versus two iStents for standalone treatment of OAG. Presented at: American Society of Cataract and Refractive Surgery annual meeting; April 13-17, 2018; Washington.

Comparing effectiveness of the Hydrus microstent to two iStents to lower IOP in phakic eyes (COMPARE). NCT02023242. https://www.clinicaltrials.gov/ct2/show/NCT02023242?term=hydrus&rank=5.

Disclosures: Chang reports he is a consultant for Ivantis. Ivantis is the sponsor of the trial.